AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Immunic Inc. (IMUX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.18

0.13 (12.38%)

At close: Feb 20, 2025, 3:59 PM

1.18

0.00%

After-hours: Feb 20, 2025, 05:46 PM EST

undefined% (undefined)

Bid	1.17
Market Cap	106.29M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.23
PE Ratio (ttm)	-0.96
Forward PE	n/a
Analyst	Buy

Ask	1.19
Volume	1,738,945
Avg. Volume (20D)	899,667
Open	1.08
Previous Close	1.05
Day's Range	1.06 - 1.19
52-Week Range	0.92 - 2.11
Beta	undefined

About IMUX

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company i...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 17, 2014

Employees 85

Stock Exchange NASDAQ

Ticker Symbol IMUX

Website https://www.immunic-therapeutics.com

Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for IMUX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 747.46% from the latest price.

Buy 85.71%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 day ago New

Immunic shares are trading higher after the compan... Unlock content with Pro Subscription

2 months ago

+7.27%

Immunic shares are trading higher after HC Wainwright initiated coverage on the stock with a Buy rating and announced a $10 price target.

News

1 day ago · proactiveinvestors.com

Immunic highlights IMU-856's potential as weight management therapy

Immunic Inc (NASDAQ:IMUX) has released new data that supports the potential of its investigational therapeutic IMU-856 as an oral treatment for weight management. IMU-856, a small molecule that target...

1 month ago · proactiveinvestors.com

Immunic eyes transformative year ahead for MS therapy vidofludimus calcium - ICYMI

Immunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio joined Proactive to discuss the company's progress in advancing its novel therapy vidofludimus calcium. He discussed the significant mile...

1 month ago · proactiveinvestors.com

Immunic eyes key data readout from multiple sclerosis trial in 2025

Immunic Inc (NASDAQ:IMUX) has reflected on key milestones achieved in 2024, including advancing its novel therapy, vidofludimus calcium, toward key data readouts and securing significant funding to pr...